The Aveni Foundation is dedicated to advancing gene-targeted therapies aimed at treating cancer and addressing other significant medical needs. The foundation emphasizes the urgency of developing innovative therapies, particularly in light of the alarming statistics surrounding cancer mortality, which is projected to escalate in the coming decades. Aveni Foundation's mission is rooted in the legacy of Fr. Joseph Aveni, who benefited from DeltaRex-G, a specific gene-targeted therapy. This highlights the foundation's commitment to not only supporting research but also facilitating access to potentially life-saving treatments for patients suffering from advanced cancers.

In addition to its focus on DeltaRex-G, the Aveni Foundation is involved in initiatives such as the "blessed protocol," which aims to expand access to this therapy for patients with advanced pancreatic cancer and sarcoma. This approach underscores the foundation's dedication to ensuring that innovative treatments reach those in need, thereby addressing the critical gaps in cancer care. Through its efforts, the Aveni Foundation seeks to foster the development of targeted therapies that can significantly improve patient outcomes and contribute to the broader fight against cancer.

United States

Aveni Foundation is a biotechnology company that focuses on expediting the development of gene-targeted therapies for cancer and Parkinson's disease.

Aveni Foundation

Company Details